nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Endophthalmitis—Riluzole—amyotrophic lateral sclerosis	0.0713	0.0713	CcSEcCtD
Apraclonidine—Blepharitis—Riluzole—amyotrophic lateral sclerosis	0.0552	0.0552	CcSEcCtD
Apraclonidine—Upset stomach—Riluzole—amyotrophic lateral sclerosis	0.0518	0.0518	CcSEcCtD
Apraclonidine—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.0345	0.0345	CcSEcCtD
Apraclonidine—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.0335	0.0335	CcSEcCtD
Apraclonidine—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.0319	0.0319	CcSEcCtD
Apraclonidine—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.0266	0.0266	CcSEcCtD
Apraclonidine—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.0244	0.0244	CcSEcCtD
Apraclonidine—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.0238	0.0238	CcSEcCtD
Apraclonidine—Asthma—Riluzole—amyotrophic lateral sclerosis	0.0213	0.0213	CcSEcCtD
Apraclonidine—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.0204	0.0204	CcSEcCtD
Apraclonidine—Infestation—Riluzole—amyotrophic lateral sclerosis	0.019	0.019	CcSEcCtD
Apraclonidine—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.019	0.019	CcSEcCtD
Apraclonidine—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.0173	0.0173	CcSEcCtD
Apraclonidine—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.0171	0.0171	CcSEcCtD
Apraclonidine—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.017	0.017	CcSEcCtD
Apraclonidine—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.0169	0.0169	CcSEcCtD
Apraclonidine—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.0168	0.0168	CcSEcCtD
Apraclonidine—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.0159	0.0159	CcSEcCtD
Apraclonidine—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.0155	0.0155	CcSEcCtD
Apraclonidine—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.0154	0.0154	CcSEcCtD
Apraclonidine—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.0152	0.0152	CcSEcCtD
Apraclonidine—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.0149	0.0149	CcSEcCtD
Apraclonidine—Tension—Riluzole—amyotrophic lateral sclerosis	0.0146	0.0146	CcSEcCtD
Apraclonidine—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.0145	0.0145	CcSEcCtD
Apraclonidine—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.0144	0.0144	CcSEcCtD
Apraclonidine—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.0138	0.0138	CcSEcCtD
Apraclonidine—Malaise—Riluzole—amyotrophic lateral sclerosis	0.0134	0.0134	CcSEcCtD
Apraclonidine—Syncope—Riluzole—amyotrophic lateral sclerosis	0.0133	0.0133	CcSEcCtD
Apraclonidine—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.0131	0.0131	CcSEcCtD
Apraclonidine—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.0126	0.0126	CcSEcCtD
Apraclonidine—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.0126	0.0126	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.0125	0.0125	CcSEcCtD
Apraclonidine—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.0125	0.0125	CcSEcCtD
Apraclonidine—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.0123	0.0123	CcSEcCtD
Apraclonidine—Oedema—Riluzole—amyotrophic lateral sclerosis	0.0121	0.0121	CcSEcCtD
Apraclonidine—Infection—Riluzole—amyotrophic lateral sclerosis	0.012	0.012	CcSEcCtD
Apraclonidine—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.0119	0.0119	CcSEcCtD
Apraclonidine—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.0118	0.0118	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.011	0.011	CcSEcCtD
Apraclonidine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.0109	0.0109	CcSEcCtD
Apraclonidine—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.0109	0.0109	CcSEcCtD
Apraclonidine—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.0108	0.0108	CcSEcCtD
Apraclonidine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.0108	0.0108	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.0105	0.0105	CcSEcCtD
Apraclonidine—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.0104	0.0104	CcSEcCtD
Apraclonidine—Pain—Riluzole—amyotrophic lateral sclerosis	0.0104	0.0104	CcSEcCtD
Apraclonidine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.0104	0.0104	CcSEcCtD
Apraclonidine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00997	0.00997	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.0099	0.0099	CcSEcCtD
Apraclonidine—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00957	0.00957	CcSEcCtD
Apraclonidine—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00892	0.00892	CcSEcCtD
Apraclonidine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00868	0.00868	CcSEcCtD
Apraclonidine—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00856	0.00856	CcSEcCtD
Apraclonidine—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00828	0.00828	CcSEcCtD
Apraclonidine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.008	0.008	CcSEcCtD
Apraclonidine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.0077	0.0077	CcSEcCtD
Apraclonidine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00762	0.00762	CcSEcCtD
Apraclonidine—Headache—Riluzole—amyotrophic lateral sclerosis	0.00758	0.00758	CcSEcCtD
Apraclonidine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00719	0.00719	CcSEcCtD
